Clinical trial
A Randomized,Blind, Positive-controlled Phase I Clinical Trial to Preliminary Evaluate the Safety and Immunogencity of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine（CRM197,TT） in Healthy People Aged 6 Weeks and Above
NCT04100772 is registered in ClinicalTrials.gov with CanSino Biologics Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized,Blind, Positive-controlled Phase I Clinical Trial to Preliminary Evaluate the Safety and Immunogencity of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine（CRM197,TT） in Healthy People Aged 6 Weeks and Above
- Lead sponsor
- CanSino Biologics Inc.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- May 18, 2020
- Completion date
- August 23, 2022
- Enrollment
- 237 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.